Aptar Acquires Nanopharm and Gateway Analytical
The acquisitions, totaling $50 million, are expected expand Aptar Pharma’s service offerings to support complex product development.
On June 10, 2019, AptarGroup announced that it has acquired two pharmaceutical services companies, Nanopharm and Gateway Analytical, for a combined price of approximately $50 million.
Nanopharm, located in Newport, UK, is a provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, PA, provides particulate detection and predictive analytical services to customers developing injectable medicines.
Both acquisitions bring complementary analytical, testing, and development services for all stages of drug development and commercialization. The acquisitions are part of Aptar’s strategy to broaden its service portfolio to support complex product development. Aptar states that the expanded services platform will enable its pharma arm to collaborate earlier with customers to support their complex drug formulations and delivery requirements.
“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” commented Gael Touya, president of Aptar Pharma, in a company press release. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial, and market-launch phases of drug development.”
Source: AptarGroup
